Xin Lang Cai Jing·2025-11-27 02:15Core Viewpoint - Nocera Biopharma has seen significant stock price growth this year, with a 112.95% increase, indicating strong market performance and investor interest [2]. Company Overview - Nocera Biopharma, established on November 3, 2015, and listed on September 21, 2022, is based in Beijing and focuses on the research, production, and commercialization of biopharmaceuticals, particularly in oncology and autoimmune diseases [2]. - The company's revenue composition includes 87.67% from drug sales, 12.04% from technology licensing, and 0.15% each from testing and R&D services [2]. Stock Performance - As of November 27, the stock price reached 26.15 CNY per share, with a market capitalization of 46.145 billion CNY [1]. - The stock has experienced a recent increase of 8.19% over the last five trading days and a 14.69% increase over the last 20 days, although it has declined by 8.28% over the past 60 days [2]. Financial Performance - For the period from January to September 2025, Nocera Biopharma reported a revenue of 1.115 billion CNY, reflecting a year-on-year growth of 59.85%, while the net profit attributable to shareholders was -64.4149 million CNY, showing a 76.61% increase in losses compared to the previous period [3]. - As of September 30, 2025, the number of shareholders increased by 8.66% to 16,500, indicating growing investor interest [3]. Institutional Holdings - As of September 30, 2025, notable institutional shareholders include: - Fuguo Precision Medical Flexible Allocation Mixed A, holding 12.1549 million shares, down 427,100 shares from the previous period [3]. - Wanjia Preferred, a new shareholder with 10 million shares [3]. - Ping An Medical Health Mixed A, also a new shareholder with 8.6266 million shares [3].